Last month, following a moderately exhausting panel on telomere lengthening at the Milken Institute, I found myself cornered by a colleague who was agonizing over how to manage her aging mother’s hypertension. She was rambling about beta-blockers, sodium intake, and the difficulty of finding a good specialist. I simply smiled, placed a hand on her shoulder, and asked: “Have you considered subjecting her cardiovascular system to the ruthless efficiency of a global asset manager?”
For decades, the wellness community has been entirely too focused on biological interventions. But this week’s announcement that Humana is selling a $2.8 billion majority stake in its CenterWell Senior Primary Care clinics to BlackRock is a paradigm shift. We are finally moving beyond the outdated notion that human senescence requires doctors, and embracing the clinical reality that it requires shareholders.
CenterWell is transitioning away from its former private equity sponsor, Welsh, Carson, Anderson & Stowe. I have nothing against the Welsh Carson protocol. As a first-line therapy for a sprawling healthcare footprint, it provided adequate capital injections. But let’s be honest: Welsh Carson is the fish oil of corporate ownership. It’s fine for baseline maintenance, but if you want to truly optimize an elderly population’s revenue yield, you need the aggressive, algorithmic restructuring that only BlackRock can provide.
I tell my patients all the time that their bodies are merely portfolios of depreciating biological assets. When a 78-year-old man comes to me complaining of joint pain, I don’t see osteoarthritis. I see an underperforming sector that requires immediate divestment. By integrating BlackRock’s ten-trillion-dollar management philosophy directly into the examination room, we can finally treat a patient’s failing kidneys with the same unsentimental liquidation strategies we use for a struggling mid-cap tech firm.
The clinical synergy is undeniable. A senior’s Medicare Advantage billing code is, fundamentally, an alternative asset class. Under the BlackRock mandate, an annual physical is no longer a tedious checklist of reflexes and blood work. It is a comprehensive fiscal audit. If a patient’s cholesterol medication threatens to drag down the clinic’s quarterly earnings, BlackRock’s algorithms seamlessly pivot the patient toward a more cost-effective, holistic solution: simply learning to live with the chest pain. It empowers the senior to take ownership of their own systemic collapse.
We view a failing pancreas not as an emotional tragedy, but as a high-yield opportunity to streamline the patient's overall biological overhead.
Naturally, the traditional medical establishment is pushing back. Critics inevitably point to a JAMA paper showing that private equity ownership of healthcare facilities is associated with higher mortality rates, reduced staffing, and worse patient outcomes. But this is a classic failure to look at the holistic picture.
What is a slight uptick in sepsis compared to a fourteen percent year-over-year growth in clinical profit margins? We have to stop defining wellness so narrowly as “whether the patient is still breathing,” and start looking at the vitality of the underlying fund. A patient may expire in the waiting room, but their properly coded final visit will live on forever in a beautifully structured collateralized debt obligation.
I was discussing exactly this over adaptogenic lattes with a senior BlackRock strategist just last Tuesday. He explained that their proprietary risk-management software, Aladdin, will now be used to evaluate whether a grandmother’s hip replacement meets the firm’s return thresholds. If her mobility doesn’t pencil out, the procedure is optimized out of existence. It is, frankly, the most beautiful, minimalist approach to preventative care I have ever seen.
If we truly love our elders, we need to stop coddling their failing organs with compassionate care. True health means surrendering your golden years to a multi-billion-dollar leveraged buyout, confident in the knowledge that your final heartbeat will be perfectly timed to maximize shareholder value.